In a large series of patients with severe kidney disease, no cases of NSF occurred after gadolinium exposure.
More than a decade ago, nephrogenic systemic fibrosis (NSF) was described in patients with advanced kidney disease who underwent contrast-enhanced MRI with gadolinium-based contrast agents (NEJM JW Gen Med Nov 15 2007 and Radiology 2007; 245:168). Thus, patients often are screened for renal impairment before they are permitted to receive gadolinium. However, studies suggest that risk for NSF is minimal with so-called “group II” agents (i.e., gadobenate dimeglumine [Multihance], gadobutrol [Gadavist], gadoterate meglumine [Doterem], gadoteridol [Prohance]).
In this single-center, retrospective study from Emory University, researchers identified 3819 patients with severe kidney disease (70% on dialysis; 30% with stage 4 or 5 chronic kidney dis…
Reviewing Author
DisclosuresNothing to disclose
DisclosuresNothing to disclose